^
    23h
    Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    23h
    Improving Chemotherapy Induced Peripheral Neuropathy in Children With Leukemia: A Study of Transcutaneous Acupoints Electrical Stimulation and Auricular Acupressure Interventions (clinicaltrials.gov)
    P=N/A, N=132, Not yet recruiting, The Hong Kong Polytechnic University
    New trial
    23h
    EUREKA-VEN: Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Centre Leon Berard | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax)
    24h
    Simultaneous chromatographic quantification of upadacitinib, nilotinib, and tryptophan decoding myeloid leukemia and liver cancer integrated with ELISA and Flow cytometry. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
    Fluorescence-based determination using flow cytometry with ELISA revealed a pioneer significant pro-apoptotic effect of Upadacitinib in HCC cells via modulation of the Bax/Bcl-2 axis with combination therapy showing superior anticancer effect compared to standard chemotherapy of Doxorubicin (DOX). Sustainability evaluation using AGREE (greenness) and BAGI (blueness) with RGB12 algorithm (whiteness) and spider-diagram visualization, in addition to the recently launched Multi-Color Assessment (MA) tool to confirm the method's multidimensional eco-efficiency in strong alignment with the United Nations Sustainable Development Goals (SDGs). This study further harnesses the Need-Quality-Sustainability (NQS) index and Koel's pyramid principles for holistic evaluation and benchmarking against reported approaches toward sustainable analytical oncology with personalized medicine.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    doxorubicin hydrochloride • Tasigna (nilotinib)
    24h
    Ribosomal protein control of hematopoietic stem cell transformation through regulation of metabolism. (PubMed, Cell Rep)
    Lin28b promotes a substantial increase in lipid content, upon which the survival of Rpl22-deficient leukemias depends. Altogether, these findings reveal that Rpl22 insufficiency enhances the leukemia potential of HSCs through regulation of FAO and promotes leukemogenesis through Lin28b promotion of lipid synthesis.
    Journal
    |
    LIN28B (Lin-28 Homolog B) • RPL22 (Ribosomal Protein L22)
    1d
    Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p Deletion. (PubMed, Am J Hematol)
    Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p Deletion.
    Journal • Real-world evidence
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    1d
    A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia. (PubMed, Leukemia)
    TCR-engineered T cells also killed patient-derived AML cells, including leukemic stem cells. In conclusion, we showed that RUNX1 frameshift mutations can be effectively targeted, demonstrating the potential relevance of TCR-based immunotherapy to treat patients with RUNX1-mutated AML.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • RUNX1 (RUNX Family Transcription Factor 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    RUNX1 mutation
    2d
    CD22 Redirected Autologous T Cells for ALL (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD22 (CD22 Molecule)
    2d
    Mitochondrial apoptosis and G0/G1-phase blockade: key mechanisms underlying triphenyltin(IV) dithiocarbamate-mediated cytotoxicity in human lymphoblastic leukemia cells. (PubMed, Sci Rep)
    OC2 also caused G0/G1 cell cycle arrest and upregulated cleaved-PARP and p21. These findings reveal the anti-proliferative ability of OC2 in a Jurkat T lymphoblastic leukemia cell model, which warrants further investigation for its antileukemic potential and therapeutic value.
    Journal
    |
    CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    2d
    Nap1L4a Cooperates with Scl/Klf1 to Recruit H2A.Z in Mediating Interactions Among Cis-Regulatory Elements and Transcription Required for Primitive Erythropoiesis in Zebrafish. (PubMed, Adv Sci (Weinh))
    Together, the findings reveal a lineage-selective transcription, with histone epigenomics-dependent role for nap1l4a in vertebrate primitive erythropoiesis. These findings highlight potential mechanisms underlying human blood disorders and hypoxia responses associated with Nap1l4a deficiency.
    Journal
    |
    KMT2C (Lysine Methyltransferase 2C) • KDM6B (Lysine Demethylase 6B)
    2d
    Disarming the Hsp70-Bim Alliance: Small-Molecule and Peptidic Disruptors of a Chaperone-Apoptotic Switch in Cancer. (PubMed, ChemistryOpen)
    A fragment-assisted screen then delivered a phenalene-dicarbonitrile chemotype, S1g-2, and optimized analogs that displace Bim with sub-micromolar potency, dismantle Hsp70-client hubs, and resensitize resistant xenografts to imatinib or tamoxifen without global proteostasis collapse. Future directions include covalent or macrocyclic wedges, degrader hybrids, and adaptive pulse-dose regimens guided by proximity-ligation assays. Collectively, chemical disarming of the Hsp70-Bim alliance exemplifies how precision targeting of chaperone PPIs can recalibrate apoptotic thresholds and unlock new therapeutic space in oncology.
    Review • Journal
    |
    BCL2L11 (BCL2 Like 11)
    |
    imatinib • tamoxifen